Views Expressed Disclaimer:

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research

Highlights

  • Cizzle Biotechnology shares surged 23.08% on 23 February 2026, driven by US commercial progress.
  • The company announced an additional USD 3.5 million in guaranteed royalty payments, bringing total minimum contract payments to USD 5.9 million.
  • Licensing partner Cizzle Bio Inc (BIO) is in the final stages of CLIA accreditation in Texas, with an application submission expected in Q2 2026.
  • A revised payment schedule reconfirms the receipt of the remaining USD 1.81 million in initial advance royalties by 31 December 2026.
  • Commercial sales of the CIZ1B biomarker test are expected to commence immediately following accreditation.

Cizzle Biotechnology Holdings PLC (LSE:CIZ) saw its share price jump 23.08% to GBX 1.60 on 23 February 2026, as investors cheered a significant commercial update regarding its expansion into the North American market.

Despite today's rally, the stock remains down approximately 11.11% over the past year. Today’s upward movement follows news of a strengthened financial agreement and imminent regulatory milestones for its early-stage lung cancer diagnostic test.

US Market Entry: CLIA Accreditation Nearing Completion

Cizzle's North American partner, Cizzle Bio Inc (BIO), is currently finalizing the Clinical Laboratory Improvement Amendments (CLIA) accreditation process. Working alongside clinical testing partner Omni Health Diagnostics Inc at their facility in Richardson, Texas, the teams are establishing operating procedures and a full validation package.

The company expects to submit the accreditation application in Q2 2026. Once submitted, accreditation is typically immediate unless further clarifications are required. Following this milestone, BIO anticipates immediate patient uptake and will report when the first commercial sales occur.

Bolstered Financial Terms and Guaranteed Royalties

The update highlighted a new, extended payment schedule that significantly increases the guaranteed capital flowing to Cizzle:

  • Initial Advance: BIO has paid USD 590,000 to date out of an initial USD 2.4 million due by the end of 2026.
  • New Guaranteed Payments: An additional USD 3.5 million in guaranteed royalties has been agreed upon for the seven-year period following the 2031 contract extension.
  • Total Commitment: The total minimum payments confirmed by BIO now stand at USD 5.9 million.

Under the current licensing agreement, Cizzle receives a 10% royalty on gross sales. The new schedule ensures a minimum of USD 500,000 per year after 2031, aligning payments with the long-term commercial scale-up of the test.

Strategic Operational Synergy

Executive Chairman Allan Syms noted that key personnel from the University of York and Cizzle have been working on-site in Texas to establish the CIZ1B biomarker test. The company believes this test will provide clinicians with a cost-effective tool for detecting lung cancer at an early stage, when it is most treatable.

While the company remains focused on the Q2 submission, it noted in its 2024 Annual Report that if the remaining USD 1.81 million in initial payments are delayed, alternative funding may be required. However, the current agreement reconfirms these payments remain on track for completion by 31 December 2026.

Market Implications

The sharp rise in share price reflects reduced uncertainty regarding Cizzle's path to revenue in the United States. By securing an additional USD 3.5 million in guaranteed future payments and set dates for CLIA submission, the company has provided a clearer financial roadmap. Investors are likely reacting to the transition from a development-phase company to a commercial-stage entity with a multi-million dollar guaranteed payment structure.

Frequently Asked Questions (FAQs)

  1. Why did Cizzle Biotechnology (LSE:CIZ) shares rise today?

The stock jumped 23.08% following news that its US partner is nearing the final stages of accreditation for its lung cancer test and has committed to an additional USD 3.5 million in guaranteed royalties.

  1. When will the CIZ1B test be available in the USA?

An application for CLIA accreditation is expected to be submitted in Q2 2026, with commercial sales anticipated to follow immediately after approval.

  1. What is the total value of the deal with Cizzle Bio Inc?

The total minimum guaranteed payments to Cizzle Biotechnology have now increased to USD 5.9 million over the duration of the contract and its subsequent extension.